Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

  • In development
  • GID-TA11963
  • Expected publication date: TBC

Status:
In progress
Technology type:
Medicine
Decision:
Selected
Prioritisation programme:
Medicines evaluation
Rationale:

Review of TA879.

Process:
STA Standard
ID number:
6680

Project Team

Project lead
Leena Issa

Email enquiries

If you have any queries please email TACommC@nice.org.uk

Timeline

Key events during the development of the guidance:

Date Update
16 February 2026 Awaiting development. Status change linked to topic prioritisation decision being set to Selected
16 February 2026 In progress. Draft scope consultation issued.

For further information on our processes and methods, please see our CHTE processes and methods manual